state that the quality of the immunofluorescence images needs to be improved and all three reviewers point out instances in which further controls are needed.
From the analysis of these comments it becomes clear that significant further work will be required before the study can be published in EMBO reports. On the other hand, given the potential interest of your findings, I would like to give you the opportunity to address the reviewers concerns and submit a revised manuscript with the understanding that the main referee concerns (as detailed above and in their reports) must be fully addressed and that acceptance of the manuscript would entail a second round of review. The length of the revised manuscript should not exceed roughly 30,000 characters (including spaces and references).
I look forward to seeing a revised form of your manuscript when it is ready.
REFEREE REPORTS:
Referee #1:
In this manuscript the authors examine the putative ferroxidase activity of a subdomain of the amyloid beta protein and its role in modifying the activity of the iron efflux protein, ferroportin. Although it was initially reported that an acidic peptide derived from APP had ferroxidase activity, subsequent studies demonstrated that the peptide did not have ferroxidase activity and those subsequent studies are confirmed here. Initial reports also indicated that the peptide derived from APP could stimulate iron efflux through Fpn, and that observation is examined here. Application of the peptide FD1 to BMVECs resulted in the increased detection of Fpn on the surface of cells and increased Fpn activity as measured by efflux of accumulated iron isotope. The addition of multicopper ferroxidases to these assays enhanced activity, and this observation was interpreted as evidence of separation of ferroxidase and Fpn stabilization activities.
The idea that APP can function as a ferroxidase is very controversial and the evidence here refuting this hypothesis is both clear and highly significant. The hypothesis put forward in this study, that sAPP can stabilize Fpn on the plasma membrane, is also intriguing and potentially significant. However, the significance of the present studies would be greatly enhanced if additional data supported their hypothesis. For example, can the authors confirm that the FD1 peptide directly binds to Fpn on the surface of cells? Can the authors demonstrate a change in the total amount of Fpn in the cells by Western blot? Alternatively, can they show a change in the subcellular localization by some other means, e.g. separation of plasma and intracellular membranes followed by Western blotting? Does hepcidin compete with the FD1 peptide for surface binding? Does full-length sAPP produce the same effects as the FD1 peptide?
Other concerns 1. On p. 5 2nd paragraph, "...the FeII and FD1 was estimated..." Shouldn't this read FeIII? 2. Immunofluorescence images are not quantitative unless specific steps are taken during imaging and image processing. The steps taken here should be indicated in the methods section.
3. Figure 5 contains labels for T1D. What is T1D? Is this the C484S Fet3 mutant? This needs to be clearly defined in the text.
Referee #2:
McCarthy et al. suggest an activity for sAPP in iron efflux in brain capillary endothelial cells. Hereby, the authors raise a controversy on data reported by Duce et al. (2010) Cell 142: 857-867 . Although the authors show that there is nor direct binding of iron to the respective APP sequence, the conclusions drawn from their experiments on sAPP functions are not justified. Studies done were only performed with the peptide FD1 that naturally does not occur and not with sAPP. Furthermore, they employ high non-physiological concentrations of the FD1 peptide. It would be interesting to see if sAPP itself and at lower concentrations could exert the same effects, which are reported for the FD1 peptide. Also, appropriate controls for the FD1 peptide were not tested, e.g. molecules with substituted residues. Another major concern is the poor image quality of the immunofluorescence data. In figure 4B the fluorescence intensity of the images differs to a great extent and shows a particular high background signal in the FD1 sample. Especially the negative control shows a much weaker staining, which prevents a direct comparison of the three images. Also, in figure 5A / sample BCS + FD1, there is no plasma membrane staining of Fpn, which contradicts the conclusions drawn from the FD1 image in 4B.
Further concerns: -In figure 4A , the authors should use a negative control to study specificity of the iron export function of FD1 (data should be validated with sAPP).
-No increase or decrease in reaction heat in ITC experiments does not necessarily exclude binding events. It is also possible that binding events do provoke only minor heat changes, which cannot be monitored with the limited sensitivity of the calorimeter Considering that the results shown in Figure 2 and 3 were already demonstrated by Ebrahimi et al. (2012) PLoS One;7(8) using the same experimental approaches, the manuscript provides novelty of data is very limited.
Referee #3:
This is an interesting report which confirms that APP is a ferroportin-binding iron exporter from Duce et al., (2010) .
They contribute to findings that the app REXXE domain does not bind iron 3+ and does not oxidize iron although they may want to check this finding with another assay.
If APP is not an iron oxidase, does this site act as a general oxidase while stabilizing ferroportin??
They have presented very interesting findings for the first ime that APP indeed stabilizes ferroportin through this domain.
The authors could well strengthen their manuscript discussion by being more rigorous to include reference that APP is linked to iron metabolism by the fact that APP mRNA binds and is regulated by iron-regulatory proteins (Cho et al., 2010) . these considerations need to be addressed to make a good paper better.. Response to Review:
Thanks to the reviewers for some excellent suggestions which have resulted in what we think is a much-improved manuscript that makes a stronger case for our hypothesis about sAPP regulation of brain capillary cell Fe-efflux. Note that we have adopted FTP, for Ferroportin Targeting Peptide, as the designation for the 22-amino acid motif in APP that binds to and stabilizes Fpn in the plasma membrane.
1) Reviewers 1 and 2 requested the following additions; all have been included in this revision:
• sAPPα (18-618) has been included to compare to the effects of FTP (327-348)
• Experiments have been repeated with 10 nM FTP and sAPPα
Thus, now included are data that show: sAPPα and FTP lead to equivalent effects on ferroportin presence in the hBMVEC plasma membrane and on 59 Fe-efflux and do so at a putative physiologic concentration (Fig. 4) . We say "putative" since quantitative data available focus primarily on Aß, not sAPP forms specifically.
• The indirect immunofluorescence imaging has been repeated using these physiological concentrations (Fig. 4) . We think these images report clearly on Fpn abundance, a concern raised by Reviewer 1. Note that most previous work with Fpn has employed vector-encoded Fpn-GFP and Fpn overexpression. We are examining the behavior of Fpn expressed at its physiologic concentration from its chromosomal locus under its endogenous promoter/enhancer elements. Also, the likely topology of Fpn puts epitopes for the best characterized commercial antibodies in a cytoplasmic location necessitating permeabilization of the cells. This results in a higher cytoplasmic background. Despite these two limitations we believe the images clearly demonstrate the stabilization of Fpn due to FTP/sAPPα and that this stabilization is comparable to that due to sCp, an effect demonstrated multiple times in the literature. Note that the end-points in our experiments are either Fpn or no Fpn and the images -and correlated Fe-efflux data -clearly define these end-points.
2) Reviewer 1 suggested demonstrating an interaction between ferroportin and FTP; we now provide data demonstrating that FTP-FLAG pulls Fpn down from hBMVEC (new Fig. 5 ). The Reviewer also asked whether this FTP-Fpn interaction was competed by hepcidin. Demonstrating this binding competition directly would be frustrated by the fact that in the presence of hepcidin, Fpn is internalized and not available on the cell surface for an interaction with FTP. One could ask the same question about the mechanism by which Cp or Hp counters the action of hepcidin. Our view is that sAPP joins these ferroxidases as cell components that stabilize Fpn to hepcidin's negative regulation by stabilizing Fpn in the plasma membrane and presenting this suggestion was a prime objective of this Report.
3) Reviewers 2 and 3 raised questions about the kinetic and ITC data in Figs II by FTP, although one could again argue that there is binding but with a very small enthalpy component. From a strictly coordination chemistry perspective, this behavior would be surprising. Frankly, we don't think FTP interacts with di-or trivalent metals at all, but our purpose was not to argue this point.
Thus, about the question of the significance of our polarographic measurements in the context of similar data for FTP given in the Ebrahimi et al paper. Our objective was to explain to the average reader -the investigator for whom understanding of sAPP and iron in the brain is critically important -why a ligand will be a ferroxidase, that is, what is required for this catalysis to occur. We show examples of such 'catalysis' (examples not provided by Ebrahimi et al) with an explanation of why some ligands are and why some are not catalysts, including FTP. We note that this is not a new concept but was well-described by Steve Aust and his co-workers over 10 years ago (Ref. 27) . We are simply bringing this behavior to the attention of the iron and neurodegeneration community in a forum likely to reach these readers. Then, with our ITC data we provide the quantitative evidence for why FTP thermodynamically can't be a 'ferroxidase.' Providing this insight isn't the point of the Ebrahimi et al experiment or paper; their objective was simply to demonstrate the lack of FTP activity in stimulating ferrous iron autoxidation. This is no reflection on their work -which was critically important to the field -but they didn't focus on the novel observation that sAPP did stimulate Fe-efflux; we have shown first what the basis of this stimulation is not and then we show what the basis of this stimulation is. That's our contribution and we are very pleased that the reviewers see the importance of and likely interest in our findings. 4) Reviewer 3 suggested the possibility that while FTP/sAPP doesn't exhibit ferroxidase activity in the polarographic quantification of ferrous iron oxidation, such activity might be stimulated upon binding to Fpn. One certainly can't discount that possibility based on any data presented here or in the literature, nor do we have any good idea about how to test it directly. However, we draw the Reviewer's attention to our experimental design in which we deplete hBMVEC of all endogenous multi-copper ferroxidase activity (Hp and Cp) by BCS treatment and then demonstrate that while addition of FTP or sAPPα stabilizes Fpn in the plasma membrane in the absence of such activity, such addition does not, by itself stimulate iron efflux. To get Fe-efflux with FTP or sAPP alone requires addition of an exogenous ferroxidase, indicating that interacting with cells does not induce such activity in either of these two species. In parallel, note that the yeast Fet3 does not, by itself, stimulate efflux because it can't bring Fpn to the membrane. By using FTP/sAPP/Fet3 in ferroxidase-negative cells (something not done by Duce et al) we have, in essence, 'fractionated' the two activities required for Fe-efflux: Fpn membrane stabilization and ferroxidase function. This experiment, including our use of the ferroxidase-negative Fet3 mutant T1D (lacking the protein's type 1 Cu atom), gets lost in the focus of the sAPP story that has captured such attention, but from our perspective, this is one of the neatest results in the literature about Fpn, ferroxidases and Feefflux. 5) Reviewer 3 also suggested that we might assess the ferroxidase activity of FTP by an additional assay. Whereas polarography quantifies O 2 depletion, the other common ferroxidase assay measurements ferrous iron depletion using the Fe(II) chelating agent, ferrozine [3-(2-pyridyl)-5,6-diphenyl-1,2,4-triazine-p,p′-disulfonic acid monosodium salt hydrate]; the Fz-Fe(II) complex exhibits absorbance at 562 nm (ε ≅ 30,000 M -1 cm -1 ). Thus, as [Fe(II)] decreases as a result of oxidation, upon addition of Fz the reaction mixture, the quantified absorbance decreases (decrease in percent Fe II remaining). Unlike the O 2 -electrode assay, this one is a single, end-point assay, not useful for kinetic analysis; however, it is more sensitive. The results of a typical Fz assay are provided in Fig. R1 using sCp as a positive, ferroxidase control. We are happy to include this figure as Supplementary Data, but don't think that it would add significantly to the results provided by the polarographic and ITC experiments, as well to the data already in the literature, in regards to the lack of FTP/sAPP ferroxidase activity. Please note that our ferroxidase assays have used FTP at 10 µM without detecting any activity; as we demonstrate in this revision, the biologic activity we observe for FTP (stabilization of Fpn on the membrane, stimulation of Fe-efflux) occurs at 10 nM. Many thanks for the submission of your revised study to EMBO reports. The manuscript was sent back to two of the original referees. As you will see from their reports, they both still raise concerns that would need to be addressed before publication. In order to make a fair and informed decision on your manuscript, I also consulted with an additional advisor in this case and discussed the remaining issues with him/her.
The advisor agreed with some of the concerns raised by the reviewers and we have agreed on, which of the requests of the referees would need to be met before publication of the manuscript in our journal.
First, both the reviewers and the advisor agreed that the co-IP experiments demonstrating an interaction between FTP and Fpn would need to be strengthened. Crucial controls (like an input control and the controls asked for by referee 1) would need to be included and the whole western blot (not just small sections) should be shown. Our advisor also raised the concern that the Fpn bands in lanes 1 and 3 run at a different position than the one in lane 2 and you would need to provide evidence that the band detected by this antibody in lane 2 is indeed Fpn that was pulleddown by FTP.
Both referees also do not feel that the quality of the immunofluorescence images in figure 4 has been sufficiently improved and I would kindly ask you to provide an alternative method, such as quantitative western blotting, to strengthen the idea that FTP stabilizes Fpn at the membrane. Finally, I would recommend including Fig 1R as supplementary information. We would, however, not require you to perform the kind of mutational analysis requested by referee 2 or to perform direct RNAi on Fpn.
I would kindly ask you to provide this additional data in the next, final version of the study and I would like to stress that acceptance of the manuscript will depend on whether or not you will be able to provide this data. Please also note that the manuscript would need to be shortened down to about 29,000 characters (it is now almost 37,000). This can, for example, be achieved by combining the results and discussion section, which avoids redundancies. The methods part should not be shortened further.
REFEREE REPORTS:
Again the methods to ensure that the indirect immunofluorescence is quantitative have not been included. The use of an alternative method to detect Fpn retention on the plasma membrane has not been provided. The authors could show a quantitative Western blot, fractionation of cellular membranes, possibly a surface biotinylation; there are many approaches possible.
The Fpn Western blot and pull-down using Flag-FTP is not persuasive. We need to see some controls that indicate that this antibody is detecting ferroportin (increased expression with Fe, stabilization with sCp, for example). Then we could interpret what we see in the pull-downs. It is concerning that only small slices of the Western blot are provided in the figure. Also, the labeling of the figure is somewhat confusing. Bound and unbound refer to proteins associated with sepharose beads and the remaining post-IP supernatant? Plus and minus signs indicate beads with and without anti-Flag antibody?
Without the supporting data regarding Fpn localization and quantity, these studies are incomplete.
Referee #2:
Unfortunately, I do not feel that the study has been sufficiently improved to warrant publication in its current form.
There are several points that must experimentally be addressed before the manuscript can be accepted for publication by a scientific journal.
The data added during the revision does not adequately address the criticism raised before. It is not clear what effect FD1/sAPP E2 is causing. Normally, a mutational analysis would be performed to map residues that are important for the biological effect seen. Such an approach is missing and experimental details how the recombinant sAPP purchased from Sigma was used and how the experiments were executed are not given. Fig. 4 is of poor quality and the effects described are not evident from the pictures shown. Moreover, the findings are indirect, e.g., knock down of Fpn by BCS is indirect and questions the data shown. siRNA would be a much better approach and a state-of-the-art method.
From data shown in fig. 5 the authors claim that FTP binds Fpn based on an IP. In addition to the low quality of the blot, a direct interaction has not been proven but is claimed.
Together, the manuscript severely suffers not only from being poorly written in some instances, but also from a lack of experimental details given, low quality of data shown and an overinterpretation of the results.
Advisor:
I now looked at the information you provided and tried to go into some of the details of the Reviewer comments. Here is what I currently think. Both Reviewers 1 and 2 raise several points that, in my view, preclude publication of this manuscript at this stage. It would certainly be easy and justified based on their comments to simply decline acceptance and publication. But I feel that both Reviewers are still open to support the publication provided that better, i.e. more convincing and more comprehensive data are included in the manuscript. I therefore think that it is fair to give the authors a final chance to convince the Reviewers (and us). I would even say, if one of these two Reviewers finally supports publication and the other one is still skeptical on some issue(s) that would be OK for me, given the critical character of the Reviewers. I would advise the authors to use the tool of supplemental files to add data that may not be central to the study but would present information to Reviewers and us that the study is well-controlled.
Some details:
1. I do not think it is fair at this stage to request mutational data on the binding site of APP on ferroportin, the more so as binding may be indirect. It may take a long time to find the relevant residues.
2. I also do not think that RNAi data need to be included for the ferroportin knockdown. Of course, this technology would be more convincing, but setting up a well-controlled RNAi study needs at least half a year to select and verify the oligos.
3. The quality of the immunofluorescence data in the pdf is indeed poor. This may in fact come from pdf conversion (?). The important thing is the quantitation, however, and that fits with the authors' claims. For me this is not a major argument against publication.
4. I agree that Fig. 5 is a rather puzzling, and needs more "data around" to convince both the Overall, I think if all the other points are addressed in a convincing fashion, I would be inclined to support acceptance of the manuscript. The authors should do as much as they can to address the missing points to make a convincing story.
Correspondence -authors 25 March 2014
Please be advised that we are preparing a second revision of this manuscript with the additions and changes that you and the advisor agreed would be needed in order for this work to be considered for publication in EMBO Reports. We appreciate your desire to make the final decision on this work in a timely fashion in order to maintain a proper timeliness to our findings. A primary concern was (and has been) the degree to which our indirect immunofluorescence images reported correctly on the plasma membrane display of ferroportin; as a complement to these images, a biochemical method was suggested, such as quantitative western blotting. Note, however, western blotting would report on all cell Fpn, not just that residing on the membrane, a value that would not demonstrate the internalization that our immunofluorescence images on intact cells is demonstrating. The surface biotinylation approach suggested by Reviewer 1 can demonstrate this change in Fpn surface expression and we have spent March perfecting this approach in our lab (we'd not used this approach previously). We have just now been successful in this and are honing the sensitivity of the approach. One aspect of our work not fully appreciated by the reviewers is that we have been examining physiologic levels of Fpn in "real" cells (not HEK293 cells transfected with a vector with FPN downstream of five CMV cis elements) and the endogenous levels of Fpn are not robust (which is why most literature studies have examined over-expressed Fpn). Also, we have used nM concentrations of sAPP and the peptide derived from it in our cell work, not the micromolar quantities used in previous work from other labs.
Another issue is that there are questions about the presentation of some data on the Fpn system, a concern that I know you share. This makes comparison of our results with the literature difficult irrespective of the strong difference in Fpn expression due to our focus on the behavior of the physiologic cell level of this protein.
Thank you for your patience, and for your assistance in the review of this manuscript.
2nd Revision -authors' response 07 April 2014
Response to Review:
Manuscript length: the MS has 31,623 characters/spaces including the text, methods, figure legends and references; without the references, the number is 21,760.
We have reduced the number of figures from 5 to 3 without removing any of the data provided.
In line with what is common in EMBO Reports, the Methods are outlined in the published manuscript and detailed in Supplementary Information. We have ensured that the legends clearly describe the experiment whose results are presented therein.
We have provided new Supplementary Information providing an additional ferroxidase assay that demonstrates the lack of this activity exhibited by the APP peptide, FTP (Fig. S1) ; the independent control requested demonstrating the specificity of our ferroportin (Fpn) antibody (Fig. S2) ; and a panel of fluorescent images illustrating the DAPI staining of the hBMVEC shown in Fig. 3 , panel A of the paper (Fig. S3) .
The co-IP experiments, Fig. 2: 1) The image of the gel is now presented without cropping and includes the molecular mass markers (panel A) 2) An input control is now provided (panel B). We note in the legend and the text that to conform to the handling of the immune-precipitate sample which resulted in an 8X concentration of the bound Fpn, this input was concentrated 10X; the recovery of Fpn indicated by these two blots indicates the efficiency of the capture of surface-exposed Fpn by the FTP-FLAG. Again, note that the independent evidence of the specificity of our Fpn antibody (Fig. S2 ) supports our conclusion that FTP-FLAG is, indeed, capturing Fpn from the hBMVEC membrane.
The indirect immunofluorescence images, Fig. 3A :
These have been repeated with images obtained at 63X rather than the 40X used previously. We think that these images correlate well with the Fe-efflux data given in Fig. 3B and hope that the reviewers concur.
We appreciated the concern about our claim concerning Fpn cell localization based solely on our indirect immunofluorescence approach and spent a month attempting to obtain convincing, quantitative data on surface biotinylation of Fpn to correlate with our IMF. We were unable to demonstrate to our satisfaction ANY Fpn biotinylation using any of the standard methods and reagents. We conclude that the steady-state fraction of endogenously expressed Fpn in the plasma membrane is small, that is, it is represented by the data in the western blot shown in Fig. 3B : most endogenous cell Fpn is a high-molecular mass, intracellular and post-translationally modified species inaccessible to either our antibody (which recognizes an extracellular loop) or any of the biotinylation reagents we employed. We didn't want to focus on this, but the fact that FTP can do what a non-specific chemical reagent can't (eg, the biotinylation reagent), namely to trap surface Fpn, convinces us that the Fpn-FTP interaction if both specific and of high affinity. Obviously, testing this inference is outside the objective of this brief report.
We emphasize that of ALL of the papers published on Fpn and its cycling, this one is the only one that examines the behavior of endogenously encoded and expressed protein: all other papers have used a model system involving either transient or stable transfectants and Fpn hyper-expression. These approaches provide pretty data, but would be inappropriate for investigation of a potentially critical physiologic regulatory mechanism. I am very pleased to accept your manuscript for publication in the next available issue of EMBO reports.
Thank you for your contribution to EMBO reports and congratulations on a successful publication. Please consider us again in the future for your most exciting work.
